<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPsych</journal-id><journal-title-group><journal-title>Open Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2161-7325</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpsych.2012.23029</article-id><article-id pub-id-type="publisher-id">OJPsych-21332</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Exorphins in urine from schizoaffective psychotics
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>ag</surname><given-names>Tveiten</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karl</surname><given-names>L. Reichelt</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Biomedical Laboratory, Sandvika, Norway</addr-line></aff><aff id="aff2"><addr-line>Department of Pediatric Research, Oslo University Hospital, Oslo, Norway</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>karlr@ulrik.uio.no(KLR)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>07</month><year>2012</year></pub-date><volume>02</volume><issue>03</issue><fpage>220</fpage><lpage>227</lpage><history><date date-type="received"><day>23</day>	<month>March</month>	<year>2012</year></date><date date-type="rev-recd"><day>21</day>	<month>April</month>	<year>2012</year>	</date><date date-type="accepted"><day>30</day>	<month>April</month>	<year>2012</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Hyperpeptiduria and opioid excess have been reported in schizophrenia. According to Prof. Dr. L. Lindstrom, Sweden opioids may explain the patho-physiology of this syndrome. Therefore it is critical to elucidate the presence and nature of opioids in schizophrenia and diagnostic sub groups. First morning urine from untreated schizoaffective patients (ICD-10: F 25.1) was separated on HPLC and peaks that elute where different opioid standards appear, freeze dried, re-dissolved in methanol/water (50/50) and 10mM formic acid. Mass spectrometry and MS/MS or fragmentation mass spectrometry was performed. We found fragmentation pattern of beta-casomorphin 1-3 and 1-4 (bovine) identical to synthetic standards from Bachem. The aggregation tendency of peptides was much in evidence. The reported exorphins were found in the urine from 8 of 12 untreated schizoaffective patients.
 
</p></abstract><kwd-group><kwd>Exorphins; Schizoaffective; Peptide; Mass-Spectrometry</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. INTRODUCTION</title><p>Increased peptide levels in urine of schizophrenic patients have been found [1-4]. Co-chromatography of exorphins with the use of different gradients on HPLC, was also reported [4,5]. Furthermore the amino acids released on acid hydrolysis indicated that the peptides contained the expected amino acids [<xref ref-type="bibr" rid="scirp.21332-ref5">5</xref>], but tryptophan was destroyed by acid hydrolysis. Opioid increase in schizophrenia has been found by several groups [1-4]. A Swedish group has convincingly described symptoms of schizophrenia related to level of opioid receptor binding opioids [<xref ref-type="bibr" rid="scirp.21332-ref6">6</xref>]. They also demonstrated human casomorphin increase in post partum psychosis [<xref ref-type="bibr" rid="scirp.21332-ref7">7</xref>], which is a very symptom rich psychosis and a depressed state. An increased peptide levels in urine from depressed patients [<xref ref-type="bibr" rid="scirp.21332-ref8">8</xref>] has also been found. With the availability of mass spectrometry and fragmentation mass spectrometry (MS/MS), the final proof of the presence and structure of various peptides, is possible. If the peptide fragmentation patterns are identical to that of synthetic standards, this is like a finger print in forensics. Urine was examined since excess of low MW compounds will usually mean overflow to the urine, and urine is a very convenient body fluid to study for the patients. Hyperpeptiduria is usually dependent on deficient break down [<xref ref-type="bibr" rid="scirp.21332-ref8">8</xref>].</p></sec><sec id="s2"><title>2. PATIENTS AND METHODS</title><p>We have over many years collected first morning urines from patients with DSM III and IV or IDC 10 diagnosed Schizophrenia. Schizoaffective depressive type psychosis (IDC 10: F25.1) was diagnosed by the leaders of Oslo Univ. Hospital., departments of psychiatry. Not treated patients were 12 of which 9 were females and 3 males, and with an age range of 37 - 58 years. It is very difficult to get hold of untreated patients, hence the total was only 12. These patients though severely depressed (hospitalized) also had a running dialogue with “a voice”, and paranoid ideation with peculiar language constructions and mannerisms. The typical social withdrawal and self-centered introversion was also present as well as rigid rituals.</p><p>Controls were hospital staff, members of The Royal guard regiment in Oslo, and student volunteers, without close relatives suffering from depression, schizophrenia or other CNS disorders. Their age range was 37 - 57: and in all 30 persons. Although adult males have lower peptide levels than females; we have here combined these with the use of 15 male and 15 female volunteers.</p><p>There is often considerable difference in eluting pattern from one patient to the next with the same diagnosis. Batches of five urines with the same diagnosis were therefore collected and re-analyzed. This trick should ensure that peaks relevant to the disease studied and common to the disorder would stay the same or increase in size, while individual peptide peaks ought to be diluted out (decrease). This technique was learned from P. Shattock o.b.e., The Autism Research Unit, Sunderland Univ., Sunderland, UK.</p><p>The fractions that appeared where synthetic standards eluted from the HPLC column or were found increased in collective HPLC re-runs, were freeze dried and kept at −15˚C.</p></sec><sec id="s3"><title>3. URINE PREPARATION</title><p>First morning urine was prepared as described [<xref ref-type="bibr" rid="scirp.21332-ref9">9</xref>]. Briefly: First morning urine was frozen as soon as possible at −15˚C. In the laboratory they were left to thaw over night in the cold room at 4˚C and pH was measured at room temp. Creatinin was determined at the Department for Medical Chemistry at Rikshospitalet (accredited). 0.8 ml urine was pre-treated by centrifugation through a 0.22 μm Cellulose acetate filter in a Spin XCentrifuge tube (Costar 8161) at 3500 &#215; g for 20 minutes at room temp. A urine volume equivalent to 250 nanomoles creatinin was analyzed by HPLC on reverse phase c-18 columns (Vydac C-18 peptide/protein column No. 201SP 54 and 0.5 &#215; 25 cm) at 30˚C. (TFA) Trifluoroacetic acid (10 mM) and an acetonitril gradient was used, and an elution rate of 1 ml/min. After a 15 min initial isocratic run to remove most amino acids and salts [<xref ref-type="bibr" rid="scirp.21332-ref10">10</xref>], a linear gradient was run from 1% to 60% acetonitril in water as described [<xref ref-type="bibr" rid="scirp.21332-ref9">9</xref>]. It is essential to have 10 mM TFA in the organic buffer to avoid steeply ascending baseline. Detection of eluting substances was performed at 215 nm (peptide bonds), 280 nm (aromatic groups) and 325 nm (Indolyl groups). In addition to point of elution we found it useful to take the 215/280 nm ratio to help with routine identification of the different peaks. Formic acid is too weak as an anion to split peptide-peptide or peptideprotein aggregates, except at concentration higher than 0.25 M [<xref ref-type="bibr" rid="scirp.21332-ref11">11</xref>].</p></sec><sec id="s4"><title>4. MASS SPECTROMETRY</title><p>The freeze dried material from peaks that had demonstrated co-chromatography with standards or increase in area after collective HPLC runs, were dissolved in 50% methanol in water by volume and 10 mM formic acid. We use locally the Pesciex quadropole with ionization in both positive and negative mode. Direct injection by micro-pump was used. It was critical to optimalize the declustering potential and collision potential for each peptide or standard used. This is to avoid splitting of the proline rich peptides by the declustering potential on ordinary MS runs as well as too much aggregation.</p></sec><sec id="s5"><title>5. ETHICAL CONSIDERATION</title><p>The Ethical committee for south-eastern Norway accepted our procedures. No NS. 06270a.</p></sec><sec id="s6"><title>6. STATISTICS</title><p>Since the number of untreated patients is small we found it best to use non-parametric statistics or the MannWhitney U test, two tailed.</p></sec><sec id="s7"><title>7. RESULTS</title><p>In <xref ref-type="fig" rid="fig1">Figure 1</xref>, the HPLC patterns for a normal and a schizoaffective patient (ICD 10: F25.1) are seen. Total area expressed as mAu under the UV 215 nm trace. in controls = 238 &#177; 86 (n = 30), while the schizoaffective patients came out with 740 &#177; 99 (n = 12) and are different with two tailed p = 0.01. As in depressions [<xref ref-type="bibr" rid="scirp.21332-ref8">8</xref>] the dominant peptide peaks elute after 48 ml (or minutes) and differ from paranoid schizophrenia where the dominant peaks are eluting earlier (less retarded) [<xref ref-type="bibr" rid="scirp.21332-ref11">11</xref>]. A urine peak corresponding to beta-casomorphin 1 - 3 was found at 47.66 &#177; 0.77 ml (n = 8) and β-casomorphin 1 - 4 (bovine) eluting at 52.81 &#177; 0.76 ml (n = 9) and the same as synthetic peptides from Bachem. The UV215/280 nm for β-casomorphin 1 - 3 was 16.42 &#177; 6, and for (bovine) β-casomorphin 1 - 4: 21.93 &#177; 1.69 for standards (N = 13).</p><p>However to our surprise both of these peptides eluted also at 61 ml, which is very close to where β-casomorphin (bovine) 1 - 7 elutes. This means that they must probably have been aggregates with each other. In the following we show the fragmentation of these peptides from this much retarded peptide peak, which were the same as for the not aggregated peaks (not shown).</p><p>In <xref ref-type="fig" rid="fig2">Figure 2</xref>, the mass spectrum of standard β casomorphin 1 - 4 (bovine) is seen (Synthesized by Bachem, Switzerland). The declustering potential was set to 20 so as to reduce splitting, which we saw at higher potentials. Even so we retained a dimer underlining the problem of adjuncts and aggregation in all peptide work [<xref ref-type="bibr" rid="scirp.21332-ref12">12</xref>].</p><p>In <xref ref-type="fig" rid="fig3">Figure 3</xref>, the fragmentation pattern (MS/MS) of β-casomorphin 1 - 3 (Y-P-F, bovine) is seen for synthetic standard in 3A and in 3B for the peptide isolated from urine of schizoaffective patients. They are identical. The X axis is expanded in the biological peptide graph (B) to check for more peptide peaks, but none was found.</p><p>In <xref ref-type="fig" rid="fig4">Figure 4</xref>, the fragmentation pattern is shown for β- casomorphin 1 - 4 (Y-P-F-P, bovine). Synthetic sample profile is labeled A, and the peptide isolated from schizoaffective urine is labeled B. Again the fragmentation patterns (MS/MS) are the same. The collision energy was decreased from 30 to 20 for B (hence we have more of the intact peptide at 523.3 m/z amu) The de-clustering potential was 20. In the upper profile A the collision energy was put at 30.</p><p>In Ffigure 5, the aggregation tendency is illustrated by the Zwitterion nature of amino acids (and even more so peptides). Attachment to proteins and other macromolecules</p><p>by peptides is extensive [12,13]. In addition adducts with Sodium. Potassium and Ammonium are quite common.</p></sec><sec id="s8"><title>8. DISCUSSION</title><p>The fragmentation pattern of a peptide is like a fingerprint and a rather clear cut demonstration of the presence of a compound. The complete identity of β-casomorphin (bovine) 1 - 3 and 1 - 4 found in the urine from schizoaffective and psychotic patients has been shown (figures 3 and 4). This finding fits similar data from depression reported elsewhere [<xref ref-type="bibr" rid="scirp.21332-ref8">8</xref>]. That most of these peptides present were found in the same peak of material eluting together and later than the standards, demonstrates the problem in peptide work caused by peptide aggregation [12,13]. Peptides like amino acids are really Zwitterions as demonstrated in figure 5. Fairly strong ionic bonds are easily formed. Also side groups that are aromatic can cause olefinic interactions (Phenylalanine, Tyrosine and Tryptophan). Furthermore Lysine, Glutemic acid, Aspartic acid, Serine and Arginine have side groups that may be ionized. In spite of 10 mM formic acid in MS buffer (figure 2) of standard β-casomorphin 1 - 4 (bovine), we still see aggregation in the form of a dimere. The simultaneous appearance of beta casomorphin 1 - 3 and 1 - 4 on the HPLC run in the same retarded peak at 61 ml, reinforces this point.</p><p>Opioid peptides can act directly on transmitter uptake and release in the CNS [<xref ref-type="bibr" rid="scirp.21332-ref1">1</xref>] and cause behavioural changes [1-4,14] in animals. Furthermore IV β-casomorphin 1 - 7 (bovine) causes FOS antigen increase in key nuclei of the brain such as the Nucl. Accumbens [<xref ref-type="bibr" rid="scirp.21332-ref15">15</xref>].</p><p>However, peptides can act as epitopes by binding to proteins and, or causing conformational changes, and thus induce antibody formation as described against diaminopeptidase IV(CD 26) reducing the efficacy of this enzyme [<xref ref-type="bibr" rid="scirp.21332-ref16">16</xref>]. It is a key enzyme in exorphins break down, and is decreased in depression [<xref ref-type="bibr" rid="scirp.21332-ref17">17</xref>].</p><p>Antibodies in serum against gluten, gliadin and casein and also complexes of antibody with these proteins have been found in schizophrenia [18-24], and bipolar disorder [<xref ref-type="bibr" rid="scirp.21332-ref25">25</xref>]. This clearly indicates uptake of these food proteins from the gut in schizophrenia and in depression, and may be a source of these peptides found.</p><p>Gastrointestinal peptide uptake is well documented [26,27], and IgA and IgG antibodies may directly demonstrate increased protein uptake. Gut uptake of proteins is also well known [26,28] and the proteins taken up from the gut are found in mothers milk [29,30]. Peptides especially opioids do pass the BBB (blood-brain barrier) [31,32], and especially since the BBB seems deficient in schizophrenia [<xref ref-type="bibr" rid="scirp.21332-ref33">33</xref>].</p><p>Antibodies against gliadin caused by gliadin peptides</p><p>or intact gliadin protein can also have direct effects on brain neurons such as Purkinje cells of the cerebellum [<xref ref-type="bibr" rid="scirp.21332-ref34">34</xref>].</p><p>Creatinin is not a very good marker to measure dilution but the best we have got so far, and not too poor in an adult population although influenced by body length and mass as well as pH (Morkrid, L. personal information).</p><p>It was surprising that the Declustering potential could fragment many of the proline rich peptides and the optimal had to be determined in each case. Similarly the collision energy had to be adjusted from one peptide to the next. This was done in steps of 10.</p></sec><sec id="s9"><title>9. CONCLUSION</title><p>Exorphins can be found in the urine from some untreated schizo-affective and psychotic patients. This confirms the suggestion by Dohan [<xref ref-type="bibr" rid="scirp.21332-ref35">35</xref>], who first suggested a connection to gliadin and casein to schizophrenia on epidemiological grounds. It also fit our data on depression [<xref ref-type="bibr" rid="scirp.21332-ref8">8</xref>] where increased levels of peptides were found and also opioids. Given the fact that there is a strong genetic input in the schizophrenias [<xref ref-type="bibr" rid="scirp.21332-ref36">36</xref>] it is unavoidable that there must be chemical changes [<xref ref-type="bibr" rid="scirp.21332-ref37">37</xref>]. Since opioids decrease dopaminergic uptake into synaptosomes and cause in vivo dopaminergic hyperactivity [<xref ref-type="bibr" rid="scirp.21332-ref1">1</xref>] the exorphins found may by causing increased dopaminergic function, relate certain food proteins to psychosis.</p></sec><sec id="s10"><title>REFERENCES</title></sec><sec id="s11"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.21332-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hole, K, Bergslien, A.A., Jorgensen, H., Berge, O.-G., Reichelt, K.L. and Trygstad, O.E. (1979) A peptide containing fraction from schizophrenia which stimulates opiate receptors and inhibits dopamine uptake. Neuroscience, 4, 1139-1147. doi:10.1016/0306-4522(79)90062-9</mixed-citation></ref><ref id="scirp.21332-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Drysdale, A., Deacon, R., Lewis, P., Olly, S., Electricwala, A. and Sherwood, R. (1982) A peptide containing fraction of plasma of schizophrenic patients which binds to opiate receptors and induces hyperactivity in rats. Neuroscience, 7, 1567-1574. 
doi:10.1016/0306-4522(82)90265-2</mixed-citation></ref><ref id="scirp.21332-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Idet</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Grof</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Menyhart</surname><given-names> J. and Pajor</given-names></name>,<name name-style="western"><surname> A. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1982</year>)<article-title>Elevated opioid activity in sera of chronic schizophrenia</article-title><source> Acta Physiologica Hungarica</source><volume> 60</volume>,<fpage> 121</fpage>-<lpage>127</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cade</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> Privette</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Fregly</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Rowland</surname><given-names> N.</given-names></name>,<name name-style="western"><surname> Sun Z.</surname><given-names> Zele</given-names></name>,<name name-style="western"><surname> V.</surname><given-names> Wagemaker</given-names></name>,<name name-style="western"><surname> H. and Edelstein</surname><given-names> C. </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>Autism and schizophrenia: Intestinal disorders</article-title><source> Nutritional Neuroscience</source><volume> 3</volume>,<fpage> 57</fpage>-<lpage>72</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref5"><label>5</label><mixed-citation publication-type="book" xlink:type="simple">Reichelt, W.H. and Reichelt, K.L. (1979) The possible role of peptides derived from food proteins in diseases of the nervous system. In: Gobbi, G., Ed., Epilepsy and Other Neurological Disorders in Celiac Disease, John Libbey &amp; Comp Ltd., London, 227-237.</mixed-citation></ref><ref id="scirp.21332-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lindstrom, L.H., Besev, G., Gunne, L.M. and Terenius, L. (1986) CSF levels of receptor active endorphins in schizophrenic patients: Correlation with symptomatology and monoamine metabolites. Psychiatry Research, 19, 93-100. doi:10.1016/0165-1781(86)90001-6</mixed-citation></ref><ref id="scirp.21332-ref7"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lindstrom</surname><given-names> L.H.</given-names></name>,<name name-style="western"><surname> Nyberg</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Terenius</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Bauer</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> Besev</surname><given-names> G.</given-names></name>,<name name-style="western"><surname> Lyrenas</surname><given-names> L.M.</given-names></name>,<name name-style="western"><surname> Wildeck-Lund</surname><given-names> E. and Lundberg</given-names></name>,<name name-style="western"><surname> B. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>CSF and Plasma beta-casomorphin like opioid peptides in postpartum psychosis</article-title><source> American Journal of Psychiatry</source><volume> 141</volume>,<fpage> 1050</fpage>-<lpage>1066</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Heiberg, T. and Reichelt, K.L. (2007) Towards a possible aetiology for depressions? Behavioral and Brain Functions, 3, 47-53. doi:10.1186/1744-9081-3-47</mixed-citation></ref><ref id="scirp.21332-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Reichelt, K.L. and Knivsberg, A.-M. (2003) Can the patho-physiology of autism be explained by the nature of the discovered urine peptides? Nutritional Neuroscience, 6, 19-28. doi:10.1080/1028415021000042839</mixed-citation></ref><ref id="scirp.21332-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bohlen</surname><given-names> P.</given-names></name>,<name name-style="western"><surname> Castillo</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Ling</surname><given-names> R. and Guillemin</given-names></name>,<name name-style="western"><surname> R. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>An efficient procedure for the separation of peptides from amino acids and salts</article-title><source> Journal of Peptide Research</source><volume> 16</volume>,<fpage> 306</fpage>-<lpage>310</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Reichelt, K.L. and Gardner, M.L.G. (2012) Genetic and dietary factors related to schizophrenia. Open Journal of Psychiatry, 2, 12-20. doi:10.4236/ojpsych.2012.21003</mixed-citation></ref><ref id="scirp.21332-ref12"><label>12</label><mixed-citation publication-type="book" xlink:type="simple">Reichelt, K.L. (2007) Low molecular—Weight peptides. In: Lahti, A., Oja, S.S., Schousboe, A. and Saransaari, P. Eds., Handbook of Neurochemistry and Molecular Neurobiology. Amino-Acids and Peptides in the Nervous System. Springer, New York, 491-511.</mixed-citation></ref><ref id="scirp.21332-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burhol</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> Jensen</surname><given-names> T.G.</given-names></name>,<name name-style="western"><surname> Florholmen</surname><given-names> T.G.</given-names></name>,<name name-style="western"><surname> Jorde</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> Vonen</surname><given-names> B. and Olsen</given-names></name>,<name name-style="western"><surname> R.I. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1986</year>)<article-title>Protein-binding and aggregation of somatostatin in human plasma</article-title><source> Italian Journal of Gastroenterology</source><volume> 19</volume>,<fpage> 1</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Z. and Cade, R.J. (1999) A peptide found in schizophrenia and autism causes behavioral changes in rats. Autism, 3, 85-95. doi:10.1177/1362361399003001007</mixed-citation></ref><ref id="scirp.21332-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Z., Cade, R.J., Fregly, M.J. and Privette, R.M. (1999) Beta-casomorphin induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism, 3, 67-83. 
doi:10.1177/1362361399003001006</mixed-citation></ref><ref id="scirp.21332-ref16"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vojdani</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> Pangborn</surname><given-names> J.B.</given-names></name>,<name name-style="western"><surname> Vojdan</surname><given-names> I.E. and Cooper</given-names></name>,<name name-style="western"><surname> E.L. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>Infections, toxic chemicals and dietary peptides binding to lymphocytes receptors and tissue enzymes are major instigators of autoimmunity in autism</article-title><source> International Journal of Immunopathology and Pharmacology</source><volume> 16</volume>,<fpage> 189</fpage>-<lpage>199</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Maes, M., Demeeester, I., Vanhhof, G., Scharpe, S., Vandervorst, C., Verkerk, R., Minner, B., Suy, E. and Raus, J. (1991) Decreased serum dipeptidyl-peptidase IV activity in depression. Biological Psychiatry, 10, 577-586. 
doi:10.1016/0006-3223(91)90027-J</mixed-citation></ref><ref id="scirp.21332-ref18"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dohan</surname><given-names> F.C.</given-names></name>,<name name-style="western"><surname> Martin</surname><given-names> I.</given-names></name>,<name name-style="western"><surname> Grasberger</surname><given-names> J.C.</given-names></name>,<name name-style="western"><surname> Boehme</surname><given-names> D. and Cottrell</given-names></name>,<name name-style="western"><surname> J.C. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1972</year>)<article-title>Antibodies to wheat gliadin in blood of psychiatric patients: Possible role of emotional factors</article-title><source> Biological Psychiatry</source><volume> 5</volume>,<fpage> 385</fpage>-<lpage>399</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Reichelt, K.L. and Landmark, J. (1995) Specific IgA antibody increases in schizophrenia. Biological Psychiatry, 37, 410-413. doi:10.1016/0006-3223(94)00176-4</mixed-citation></ref><ref id="scirp.21332-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Leister, F., Yang, S., Krivogorsky, B., Alasedini, A. and Yolken, R. (2010) Markers of Gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biological Psychiatry, 58, 100-104. doi:10.1016/j.biopsych.2010.03.021</mixed-citation></ref><ref id="scirp.21332-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Samaroo, D., Dickerson, F., Kasarda, D.D., Green, P.H.R., Briani, C., Yolken, R.H. and Alaedini, A. (2010) Novel immune response to gluten in individuals with schizophrenia. Schizophrenia Research, 118, 248-255.  
doi:10.1016/j.schres.2009.08.009</mixed-citation></ref><ref id="scirp.21332-ref22"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jin</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Wu</surname><given-names> N.</given-names></name>,<name name-style="western"><surname> Xu</surname><given-names> Q.</given-names></name>,<name name-style="western"><surname> Zhang</surname><given-names> X.</given-names></name>,<name name-style="western"><surname> Ju</surname><given-names> G.-Z.</given-names></name>,<name name-style="western"><surname> Law</surname><given-names> M.H. and Wei</given-names></name>,<name name-style="western"><surname> J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2011</year>)<article-title>A study of circulating gliadin antibodies in schizophrenia among Chinese population</article-title><source> Schizophrenia Bulletin</source><volume> 37</volume>,<fpage> 748</fpage>-<lpage>752</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Niebuhr, D.W., Li,Y., Cowan, D.N.,Weber, N.S., Fisher, J.A., Ford, G.M. and Yolken, R. (2011) Association between bovine casein antibody and new onset schizophrenia among US military personnel Association between bovine casein antibody and new onset schizophrenia among US military personnel. Schizophrenia Research, 128, 51-55. doi:10.1016/j.schres.2011.02.005</mixed-citation></ref><ref id="scirp.21332-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Severance, E.G., Lin, J., Sampson, H.A., Gimenez, G., Dickerson, F.B., Halling, M., Gresitt, K., Halle, J., Stallings, C.R., Origoni, P.P., Dupont, D. and Yolken, R.H. (2011) Dietary antigens, epitope recognition,and immune complex formation in recent onset psychosis and long-term schizophrenia. Schizophrenia Research, 126, 43-50. doi:10.1016/j.schres.2010.12.001</mixed-citation></ref><ref id="scirp.21332-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Severance, E.G., Dupont, D., Dickerson, F.B., Stallings, C.R., Origoni, A.E., Krivgorski, B., Yang, S., Hansnoot, W. and Yolken, R.H. (2010) Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disorders, 12, 834-842. doi:10.1111/j.1399-5618.2010.00879.x</mixed-citation></ref><ref id="scirp.21332-ref26"><label>26</label><mixed-citation publication-type="book" xlink:type="simple">Gardner, M.L.G. (1994) Absorption of intact proteins and peptides. In: Johnson, L.R. Ed., Physiology of the Gastrointestinal Tract, Raven Press, New York, 1795-1820.</mixed-citation></ref><ref id="scirp.21332-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Chabance, B., Marteau, P., Rambaud, J.C., Migliore-Samour, D., Boynard, M., Perrotin, P., Guillet, R., Jolles, P. and Fiat, A.M. (1998) Casein peptides release and passage to the blood in humans during digestion of milk and yogurt. Biochimie, 80, 155-165. 
doi:10.1016/S0300-9084(98)80022-9</mixed-citation></ref><ref id="scirp.21332-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Husby, S., Jensenius, J.C. and Svenhag, S.E. (1985) Passage of undegraded dietary antigen into the blood of healthy adults. Scandinavian Journal of Immunology, 22, 83-92. doi:10.1111/j.1365-3083.1985.tb01862.x</mixed-citation></ref><ref id="scirp.21332-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Kilshaw, P.J. and Cant, A.J. (1984) The passage of maternal dietary protein into human breast milk. International Archives of Allergy and Applied Immunology, 75, 8-15. doi:10.1159/000233582</mixed-citation></ref><ref id="scirp.21332-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Troncone, R., Scarcello, A., Donatiello, A., Cannataro, P., Tabusco, A. and Auricchio, S. (1987) Passage of gliadin into human breast milk. Acta Paediatrica Scandinavica, 76, 453-456. doi:10.1111/j.1651-2227.1987.tb10498.x</mixed-citation></ref><ref id="scirp.21332-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Ermisch, A., Brust, P., Kretzchmar, R. and Buhle, H.-J. (1983) On the blood-brain barrier to peptides (3H) beta-casomorphin-5 uptake by eighteen brain regions in vivo. Journal of Neurochemistry, 41, 1229-1233. 
doi:10.1111/j.1471-4159.1983.tb00816.x</mixed-citation></ref><ref id="scirp.21332-ref32"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banks</surname><given-names> W.A. and Kastin</given-names></name>,<name name-style="western"><surname> A.J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Peptide transport systems for opiates across the blood-brain barrier</article-title><source> American Journal of Physiology</source><volume> 259</volume>,<fpage> E1</fpage>-<lpage>E16</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref33"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kirch</surname><given-names> D.G.</given-names></name>,<name name-style="western"><surname> Alexander</surname><given-names> R.C.</given-names></name>,<name name-style="western"><surname> Suddath</surname><given-names> N.R.I.</given-names></name>,<name name-style="western"><surname> Papadopoulos</surname><given-names> N.M.</given-names></name>,<name name-style="western"><surname> Kaufmann</surname><given-names> C.A.</given-names></name>,<name name-style="western"><surname> Wyatt</surname><given-names> D. and Wyatt</given-names></name>,<name name-style="western"><surname> R.J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1992</year>)<article-title>Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia</article-title><source> Journal of Neural Transmission</source><volume> 89</volume>,<fpage> 219</fpage>-<lpage>232</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.21332-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Hadjivassiliou, M., Boscolo, S., Davies-Jones, G.A.B., Grünewald, R.A., Not, T., Sanders, D.S., Simpson, L.E., Tongiorgi, E., Williamson, C.A. and Woodroofe, N.M. (2002) The humoral response in the pathogenesis of gluten ataxia. Neurology, 58, 1221-1226. 
doi:10.1212/WNL.58.8.1221</mixed-citation></ref><ref id="scirp.21332-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Dohan, F.C. (1966) Cereals and schizophrenia.Data and hypothesis. Acta Psychiatrica Scandinavica, 42, 125-152. 
doi:10.1111/j.1600-0447.1966.tb01920.x</mixed-citation></ref><ref id="scirp.21332-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Onstad, B., Skre, I., Torgersen, S. and Kringlen, E. (1991) Twin concordance for DSMIII R Schizophrenia. Acta Psychiatrica Scandinavica, 83, 396-401.  
doi:10.1111/j.1600-0447.1991.tb05563.x</mixed-citation></ref><ref id="scirp.21332-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Reichelt, K.L., Seim, A.R. and Reichelt, W.H. (1996) Could schizophrenia be reasonably explained by Dohan’s hypothesis on genetic interaction with a dietary peptide overload? Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry, 20, 1083-1114.</mixed-citation></ref></ref-list></back></article>